ArticleCureus2025
Evaluation of miRNA-210 as a Prognostic Biomarker for Pre-eclampsia: A Case-Control Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting the GSK-3β/mTOR axis: a novel pharmacological strategy for preeclampsia prevention and treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- The Role of microRNA-210 in the Pathogenesis and Diagnosis of Preeclampsia-A Systematic Review.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPre-eclampsia (PE) is a complex, multisystem disorder occurring during pregnancy and remains a significant cause of maternal and perinatal morbidity and mortality. Despite its clinical importance, the underlying molecular mechanisms contributing to the development of PE are not fully understood. Specific microRNAs, such as miRNA-210, may play a crucial role in the pathophysiology of PE.
objectiveThis study investigates the potential utility of miRNA-210 as a biomarker for the early detection and risk prediction of PE. MATERIALS AND
methodsThis case-control study was conducted from April 2023 to February 2025 and involved PE and normotensive pregnant women admitted to the Department of Obstetrics and Gynecology at Shri BM Patil Medical College Hospital and Research Centre, Bijapur Lingayat District Educational Association (BLDE) (Deemed to be University), Vijayapura. Women who met the inclusion criteria were enrolled after providing written informed consent. A total of 102 pregnant women participated, divided into two groups: Group 1 included 51 women diagnosed with PE, and Group 2 comprised 51 normotensive pregnant women matched for age (±5 years), gestational age (±1 week), and obstetric score, serving as the control group. All participants underwent detailed history-taking, clinical examinations, and laboratory investigations, including coagulation profile, liver function test, renal function test, complete blood count, proteinuria evaluation, and miRNA-210 gene expression analysis via reverse transcription-polymerase chain reaction. A peripheral venous blood sample was collected at admission and submitted for genetic analysis. After genetic analysis, study parameters were compared, and maternal and neonatal outcomes were observed.
resultsIndividuals with PE exhibited a statistically significant elevation in serum miRNA-210 levels (p<0.001) compared to the control group. miRNA-210 demonstrated a highly significant positive correlation with systolic blood pressure, mean arterial blood pressure, diastolic blood pressure, serum protein, serum uric acid, serum albumin, and serum alkaline phosphatase. However, no significant correlation was observed with hemoglobin percentage, platelet count, international normalized ratio, or serum creatinine. The area under the curve was 0.994, with a 95% confidence interval ranging from 0.985 to 1.0. At a cut-off value of 9.63-fold change, serum miRNA-210 levels showed a sensitivity of 100% and a specificity of 96.1%, with positive and negative predictive values of 96.2% and 100%, respectively.
conclusionsElevated serum miRNA-210 levels were observed in women with PE compared to normotensive pregnant women. Thus, serum miRNA-210 may serve as a non-invasive diagnostic and predictive biomarker in PE and contribute to a better understanding of its etiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.